

Healthy Volunteers

**A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight**

**Trial Status**  
Not yet recruiting

**Trial Runs In**

**Trial Identifier**  
NCT07499050 YP46260

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

**Official Title:**

An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

**Trial Summary:**

This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

**NCT07499050 YP46260**  
Trial Identifiers

**Eligibility Criteria:**

**Gender**  
All

**Age**  
#18 Years & # 65 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

**Inclusion Criteria:**

- Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
- Participants who are ethnically Chinese and living in mainland China

# ForPatients

*by Roche*

- Body mass index (BMI)  $\geq 24$  kg/m<sup>2</sup> at screening
- Agreement to adhere to the contraception requirements

## ***Exclusion Criteria:***

- Any medical condition or disease that could be expected to progress, recur, or change to such an extent that it could bias the assessment of the clinical or mental status of the participant to a significant degree or put the participant at special risk in the opinion of the Investigator. Such conditions may include clinically significantly impaired endocrine, thyroid, hepatic, respiratory, or renal function for any reason, unstable diabetes mellitus and insulin dependent diabetes mellitus, clinically significant cardiovascular disease, pheochromocytoma, or history of any psychotic mental illness.